Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2026)
Quarterly results put Total Current Liabilities at $30.3 million for Q1 2026, up 5.23% from a year ago — trailing twelve months through Mar 2026 was $30.3 million (up 5.23% YoY), and the annual figure for FY2025 was $33.5 million, up 10.63%.
Solid Biosciences has reported Total Current Liabilities over the past 10 years, most recently at $30.3 million for Q1 2026.
- Total Current Liabilities reached $30.3 million in Q1 2026 per SLDB's latest filing, down from $33.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $36.3 million in Q3 2025 and bottomed at $14.3 million in Q1 2024.
- Median Total Current Liabilities over the past 5 years was $21.7 million (2022), compared with a mean of $23.0 million.
- The largest annual shift saw Total Current Liabilities crashed 35.5% in 2023 before it surged 108.42% in 2024.
- Over 5 years, Total Current Liabilities stood at $22.5 million in 2022, then plummeted by 35.5% to $14.5 million in 2023, then soared by 108.42% to $30.3 million in 2024, then increased by 10.63% to $33.5 million in 2025, then dropped by 9.53% to $30.3 million in 2026.
- Business Quant data shows Total Current Liabilities for SLDB at $30.3 million in Q1 2026, $33.5 million in Q4 2025, and $36.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.28 Mn |
| Dec 31, 2025 | 33.47 Mn |
| Sep 30, 2025 | 36.34 Mn |
| Jun 30, 2025 | 29.85 Mn |
| Mar 31, 2025 | 28.78 Mn |
| Dec 31, 2024 | 30.26 Mn |
| Sep 30, 2024 | 22.85 Mn |
| Jun 30, 2024 | 14.69 Mn |
| Mar 31, 2024 | 14.34 Mn |
| Dec 31, 2023 | 14.52 Mn |
| Sep 30, 2023 | 15.82 Mn |
| Jun 30, 2023 | 15.87 Mn |
| Mar 31, 2023 | 20.29 Mn |
| Dec 31, 2022 | 22.51 Mn |
| Sep 30, 2022 | 16.93 Mn |
| Jun 30, 2022 | 21.72 Mn |
| Mar 31, 2022 | 21.74 Mn |
| Dec 31, 2021 | 23.60 Mn |
| Sep 30, 2021 | 22.54 Mn |
| Jun 30, 2021 | 22.55 Mn |
| Mar 31, 2021 | 22.83 Mn |
| Dec 31, 2020 | 24.48 Mn |
| Sep 30, 2020 | 14.77 Mn |
| Jun 30, 2020 | 13.17 Mn |
| Mar 31, 2020 | 12.88 Mn |
| Dec 31, 2019 | 18.28 Mn |
| Sep 30, 2019 | 16.75 Mn |
| Jun 30, 2019 | 13.67 Mn |
| Mar 31, 2019 | 14.57 Mn |
| Dec 31, 2018 | 12.48 Mn |
| Sep 30, 2018 | 10.64 Mn |
| Jun 30, 2018 | 8.68 Mn |
| Mar 31, 2018 | 9.93 Mn |
| Dec 31, 2017 | 11.27 Mn |